Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks seen lower as investors mull GDP data

(Sharecast News) - London stocks were set to fall at the open on Friday following a downbeat session on Wall Street, as investor mull the latest UK GDP data. The FTSE 100 was called to open 26 points lower at 7,885.

Figures out earlier from the Office for National Statistics showed the UK narrowly avoided a technical recession at the end of last year, after the economy stagnated in the last quarter of 2022.

GDP fell 0.5% in December following growth of 0.1% in November and 0.55% in October. December's print was dragged down by a 0.8% decline in the services sector, which recorded falls in health, education, transport and storage, arts and entertainment.

However, it was not enough to push the quarterly data into negative territory, and GDP was 0.0% in the three months to December, following a decline of 0.3% in November.

The definition of a recession is two consecutive quarters of contraction.

Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown, said: "While the absence of an official label will be seen as a victory, there's an argument to say the can has simply been kicked further down the road. The ramifications for consumers are also tough: around 7m households are still expected to struggle to pay energy and food bills, technical recession or not."

In corporate news, FirstGroup said it had been granted a two-year extension for its South Western Railway franchise, by the UK government.

The contract, which began in May 2021, will now run until May 25 2025 on existing terms, the company said.

Drugmaker GSK's mismatch repair-deficient recurrent or advanced endometrial cancer treatment has been granted full approval by the US Food and Drug Administration.

GSK said Jemperli's approval comes hot on the heels of long-term outcome results from its GARNET phase I trial, which demonstrated an overall response rate of 45.4%.

Share this article

Related Sharecast Articles

London open: Stocks gain as investors mull Rightmove data; inflation eyed
(Sharecast News) - London stocks edged higher early trade on Monday as investors mulled the latest UK house price figures and looked ahead to key inflation data later in the week.
London pre-open: Stocks seen up as investors mull Rightmove data
(Sharecast News) - London stocks were set to rise at the open on Monday as investors mulled the latest UK house price figures.
London close: Stocks recoup some earlier losses
(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.
London midday: FTSE stays down; Auto Trader hit by downgrade
(Sharecast News) - London stocks were still in the red by midday on Friday, having taken their opening cue from a downbeat close on Wall Street.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.